Cargando…

Comprehensive Analysis of PPMs in Pancreatic Adenocarcinoma Indicates the Value of PPM1K in the Tumor Microenvironment

SIMPLE SUMMARY: Pancreatic adenocarcinoma is a devastating disease, with an extremely poor survival rate worldwide. Its poor responsiveness to chemotherapy and immunotherapy has a bearing on the unique tumor microenvironment. Our study demonstrates that Metal-dependent protein phosphatases (PPMs) be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Yanyan, Lan, Sihua, Zhong, Wa, Huang, Fengting, Peng, Juanfei, Zhang, Shineng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856814/ https://www.ncbi.nlm.nih.gov/pubmed/36672423 http://dx.doi.org/10.3390/cancers15020474

Ejemplares similares

METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma
por: Lu, Liting, et al.
Publicado: (2022)

CircMYOF triggers progression and facilitates glycolysis via the VEGFA/PI3K/AKT axis by absorbing miR-4739 in pancreatic ductal adenocarcinoma
por: Zheng, Dandan, et al.
Publicado: (2021)

SLC45A4 promotes glycolysis and prevents AMPK/ULK1‐induced autophagy in TP53 mutant pancreatic ductal adenocarcinoma
por: Chen, Wenying, et al.
Publicado: (2021)

LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis
por: Huang, Fengting, et al.
Publicado: (2018)

Hepatic perivascular epithelioid cell neoplasm: A clinical and pathological experience in diagnosis and treatment
por: Chen, Wenying, et al.
Publicado: (2017)

Retraction Note to: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis
por: Huang, Fengting, et al.
Publicado: (2022)

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
por: Arnold, Douglas L, et al.
Publicado: (2022)

MiR-196a Promotes Pancreatic Cancer Progression by Targeting Nuclear Factor Kappa-B-Inhibitor Alpha
por: Huang, Fengting, et al.
Publicado: (2014)

Comparison of Disease Activity in SPMS and PPMS in the Context of Multicenter Clinical Trials
por: Orbach, Rotem, et al.
Publicado: (2012)

Hydroxychloroquin könnte die Progression der Behinderung bei PPMS verzögern
por: Menge, Til
Publicado: (2021)

Primary Esophageal Lymphoma: Clinical Experience in Diagnosis and Treatment
por: Qu, Junchi, et al.
Publicado: (2021)

The MRI central vein marker; differentiating PPMS from RRMS and ischemic SVD
por: Samaraweera, Amal P.R., et al.
Publicado: (2018)

A comparison of clinical outcomes in PPMS in the INFORMS original trial data set
por: Koch, Marcus W, et al.
Publicado: (2021)

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set
por: Koch, Marcus W., et al.
Publicado: (2017)

Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis
por: Zhuan-Sun, Yongxun, et al.
Publicado: (2017)

PPMS: A framework to Profile Primary MicroRNAs from Single-cell RNA-sequencing datasets
por: Ji, Jiahui, et al.
Publicado: (2022)

Development of a Fully Automated, GPS Based Monitoring System for Disaster Prevention and Emergency Preparedness: PPMS(+RT)
por: Bond, Jason, et al.
Publicado: (2007)

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders
por: Engel, Sinah, et al.
Publicado: (2020)

Prognostic and immunological potential of PPM1G in lung adenocarcinoma
por: Yin, Rongjiang, et al.
Publicado: (2023)

Workshop on PPM
Publicado: (1978)

PPM LPI
por: Frammery, B
Publicado: (1987)

PPM LPI
Publicado: (1987)

Prognostic value of biomarkers in the tumor microenvironment of pancreatic ductal adenocarcinoma
por: Mishra, Nitish K., et al.
Publicado: (2020)

Comprehensive analysis of prognostic immune-related genes associated with the tumor microenvironment of pancreatic ductal adenocarcinoma
por: Yan, Shibai, et al.
Publicado: (2020)

AA - PPM No. 4
por: Benincasa, G P
Publicado: (1983)

NAPS : RT-PPM
Publicado: (1985)

Targeting Pancreatic Ductal Adenocarcinoma Acidic Microenvironment
por: Cruz-Monserrate, Zobeida, et al.
Publicado: (2014)

A Comprehensive Transcriptional Signature in Pancreatic Ductal Adenocarcinoma Reveals New Insights into the Immune and Desmoplastic Microenvironments
por: Pérez-Díez, Irene, et al.
Publicado: (2023)

Comprehensive analysis of Cuproplasia and immune microenvironment in lung adenocarcinoma
por: Kuang, Junjie, et al.
Publicado: (2023)

PPM = Software en "C"
Publicado: (1986)

Le PPM au Booster
por: Benincasa, G
Publicado: (1978)

PPM au niveau LPI
Publicado: (1985)

PLS et PPM LPI
Publicado: (1986)

PPM dans les SMACC
Publicado: (1986)

Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma
por: Kiryu, Sachie, et al.
Publicado: (2021)

Comprehensive Analysis of 5-Methylcytosine (m(5)C) Regulators and the Immune Microenvironment in Pancreatic Adenocarcinoma to Aid Immunotherapy
por: Wang, Ronglin, et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma: The Characteristics of Contrast-Enhanced Ultrasound Are Correlated with the Hypoxic Microenvironment
por: Wang, Lan, et al.
Publicado: (2023)

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
por: Smith, Caitlyn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1l0cge06597lalfgnp4hg7j0hr